Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation

Cornea

Volumn 34, Issue 3, 2015, Pages 243-247

  Shikari, Hasanain ^a   Amparo, Francisco ^a   Saboo, Ujwala ^a   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplant; Dry eye; Ocular graft versus host disease

Indexed keywords

HLA ANTIGEN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASSESSMENT OF HUMANS; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR GRAFT VERSUS HOST REACTION; OCULAR SURFACE DISEASE; ORGAN DONOR; OSDI SCORE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIRMER SCORE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; DONOR; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

ADULT; AGED; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84923558522     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000340     Document Type: Article

References (35)

1. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
2. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1998;21:273-279.
3. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373:1550-1561.
4. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol. 2006;17:344-348.
5. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233-251.
6. Ivanir Y, Shimoni A, Ezra-Nimni O, et al. Prevalence of dry eye syndrome after allogeneic hematopoietic stem cell transplantation. Cornea. 2013;32:e97-e101.
7. Jacobs R, Tran U, Chen H, et al. Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Bone Marrow Transplant. 2012;47:1470-1473.
8. Westeneng AC, Hettinga Y, Lokhorst H, et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea. 2010;29: 758-763.
9. Dietrich-Ntoukas T, Cursiefen C, Westekemper H, et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on clinical practice in chronic GVHD. Cornea. 2012;31:299-310.
10. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98: 1695-1700.
11. Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol. 1983;101:580-584.
12. Bradfield YS, Kushner BJ, Gangnon RE. Ocular complications after organ and bone marrow transplantation in children. J AAPOS. 2005;9: 426-432.
13. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf. 2005;3:203-211.
14. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83:1125-1130.
15. Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) working party on late effects. Bone Marrow Transplant. 1996;17:1105-1111.
16. Pinschmidt NW. Evaluation of the schirmer tear test. South Med J. 1970; 63:1256.
17. Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33:1031-1035.
18. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol. 1989;107:1343-1348.
19. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004;15:503-507.
20. Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology. 2009;116:1624-1629.
21. Stevenson W, Shikari H, Saboo US, et al. Bilateral corneal ulceration in ocular graft-versus-host disease. Clin Ophthalmol. 2013;7:2153-2158.
22. Inagaki E, Ogawa Y, Matsumoto Y, et al. Four cases of corneal perforation in patients with chronic graft-versus-host disease. Mol Vis. 2011;17:598-606.
23. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versushost disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30:3202-3308.
24. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281-285.
25. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576-4583.
26. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51:443-447.
27. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
28. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997;350:767-771.
29. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-2068.
30. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1997;90:1410-1414.
31. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119-125.
32. Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997;90:2962-2968.
33. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2006;38:223-227.
34. Chang AY, Ko M, Johnston L, et al. Risk factors for the development of ocular graft versus host disease after hematopoietic cell transplantation. Paper presented at: Association for Research in Vision and Ophthalmology Annual Conference Ft; 2012; 6 May 2012, Lauderdale, FL.
35. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601-1605.